Software Earnings, GLP-1s, Longevity Medicine, OpenAI's Hiring Platform, and Nvidia's Circular Business

Enterprise Software Trends

• 💡 Infrastructure software (e.g., MongoDB, Snowflake) shows strong performance, indicating that software is not "dead" despite AI advancements.
• ⚠️ Concerns are rising about seat-based models shifting to consumption and the impact of AI search on the top-of-funnel for PLG/self-service companies like HubSpot and Intuit.
• 📈 Large enterprise software companies face slowing growth due to a post-COVID digestion period, an "AI crowding out effect" (shifting focus to AI strategy), and the law of large numbers.
• 🚀 Incumbents can pursue growth through AI-native solutions (even if it means cannibalizing existing business) and strategic AI-focused M&A (e.g., Service Now, Nice).
• ⏳ AI monetization for large companies is a long-term play, expected to take years rather than quarters, due to product development, use case identification, and addressing security, governance, and data privacy concerns.

GLP-1s and the Tech Elite

• 📊 A survey revealed 50.5% of The Information's readers (a tech-forward audience) are taking GLP-1s (Ozempic, Wegovy), often for reasons beyond medical necessity.
• 🧠 Users report significant mental and lifestyle benefits, including enhanced focus, increased energy, and a reduction in "food noise," which frees up mental capacity.
• ✅ Personal accounts detail remarkable metabolic improvements, such as drastically reduced cholesterol and triglycerides, lower blood pressure, and a significant decrease in metabolic age.
• 💸 Accessing these drugs can be costly, often $1,000 per month initially and typically not covered by insurance, with telemedicine providers facilitating prescriptions.
• 🔬 A biohacking trend involves individuals experimenting with micro-dosing GLP-1s for focus, though experts caution about the newness of the drugs and the need for more long-term studies.
• 🌱 A new market is emerging for CPG brands offering healthier products (e.g., Magna for hydration, Gruns for superfoods) to cater to the changing dietary needs and behaviors of GLP-1 users.

Advancing Longevity Medicine

• 🧬 New Limit, co-founded by Brian Armstrong and Jacob Kimmel, is a genomics company focused on epigenetic reprogramming to restore youthful cellular function.
• 💡 The science aims to reset chemical marks on DNA (the epigenome) that dictate gene expression, which degrade with age, causing cells to lose function.
• 💊 The company is developing medicines (likely IV-administered, infrequent doses) that activate specific transcription factors to reset the epigenome, making cells function as they did when young.
• 🎯 The first medicine targets hepatocytes (liver cells) to restore youthful function, initially for severe liver disease, with potential to expand to conditions like metabolic syndrome.
• ⏳ The goal is to add 1-2 years of healthy life, with the first product aiming for clinical trials by 2028, suggesting reprogramming medicines could be available within a decade.

OpenAI's Hiring Ambitions

• 💼 OpenAI is reportedly developing a hiring platform to rival LinkedIn, an announcement made well in advance of a tangible product.
• 🗣️ This initiative is viewed partly as a PR strategy to address concerns about AI's impact on jobs and to position OpenAI as a facilitator of employment.
• 🚀 Hyper-growth companies often launch numerous products due to internal momentum, talent acquisition, and abundant resources, though many may not achieve widespread success.
• 🛠️ The speaker's company, Standard Aptitude, offers AI-powered hiring solutions that prioritize skill-based testing over traditional credentials, combating issues like fake resumes and cheating.
• 🔮 The future of hiring will emphasize **